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Fluorescence photodetection (PD) and photodynamic therapy
(PDT) are techniques currently under clinical assessment for both
visualization and local destruction of malignant tumours and prema-
lignant lesions. One drawback of these methods found with some
photosensitizers is a more or less long-term cutaneous photosensi-
tivity (Wagnières et al, 1998; Dougherty et al, 1990). A more recent
strategy for administering photosensitizers involves the application
of 5-aminolaevulinic acid (ALA) in order to stimulate the formation
of protoporphyrin IX (PpIX) in situ. The exogenous ALA bypasses
the negative feedback control from haem to ALA synthase that
catalyses the condensation of glycine and succinyl–coenzyme A
(CoA). Given in excess, exogenous ALA thus can result in a tempo-
rary accumulation of PpIX, in particular, in cells with higher meta-
bolic turnover. Since PPIX has fairly good photosensitizing
properties (Cox et al, 1982; Kennedy et al, 1990) proposed ALA as
a possible photodynamic agent. Following this pioneering work, this
treatment modality has been widely studied for various cancers
(Kennedy et al, 1992; Peng et al, 1992; Svanberg et al, 1994).
As well as for the PDT of malignant or premalignant lesions,
ALA-induced PpIX is now being used for the detection of such
lesions. This technique has been shown to work, among other
applications, in urology, where easy instillation in the bladder,
combined with the fact that this organ is readily accessible endo-
scopically, makes it an ideal object. Alongside classical techniques
such as cytology or white light examination, fluorescence PD by
ALA-induced PpIX provides some advantages (Leveckis et al,
1994; Kriegmair et al, 1996; Jichlinski et al, 1997). This inspection
modality allows an exact mapping which pinpoints, with a high
level of sensitivity and specificity, the locations of carcinoma in
situ (CIS) as well as early stages of cancer-like dysplasias, which
are normally difficult to recognize under white light examination.
However, when using topically instilled ALA for the PDT of CIS
and precancerous lesions, this modality appears to be limited by the
amount of ALA that enter the target cells or by the tissue penetration
and the distribution of the resulting PpIX in the targeted tissue.
Almost all of these possible disadvantages accompanying the use of
ALA can be ascribed to the physical–chemical properties of the
molecule itself. Applied under physiological conditions, ALA is a
zwitterion (Novo et al, 1996). Because the lipid bilayer of biological
membranes is relatively impermeable to charged molecules, the
cellular uptake of ALA is shallow. Consequently, in order to
increase the transport across cellular membranes, fairly high drug
doses and increased administration times have to be used. This
deficiency results in a low penetration depth (Warloe et al, 1992;
Loh et al, 1993; Peng et al, 1995) and an ALA-induced PpIX distri-
bution, which is not optimized for the PDT of the deep layers of
nodular lesions in the urothelium (Iinuma et al, 1995; Chang et al,
1996) after topical ALA application.
Systematic studies have shown that the modification of a drug to
an ester, an amide or a urethane by the addition of a long-chain
hydrocarbon improves penetration through biological barriers
(Bridges et al, 1979; Jain, 1987a, 1987b). After penetration into
the cell, the ester derivative can then, for example, be hydrolysed
back to the free ALA by non-specific esterases. Recently,
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SummaryExogenous administration of 5-aminolaevulinic acid (ALA) is becoming widely used to enhance the endogenous synthesis of
protoporphyrin IX (PpIX) in photodynamic therapy (PDT) and fluorescence photodetection (PD). Recently, results have shown that the
chemical modification of ALA into its more lipophilic esters circumvents limitations of ALA-induced PpIX like shallow penetration depth into
deep tissue layers and inhomogeneous biodistribution and enhances the total PpIX formation. The present clinical pilot study assesses the
feasibility and the advantages of a topical ALA ester-based fluorescence photodetection in the human bladder. In this preliminary study 5-
aminolaevulinic acid hexylester (h-ALA) solutions, containing concentrations ranging from 4 to 16mM, were applied intravesically to 25
patients. Effects of time and drug dose on the resulting PpIX fluorescence level were determined in vivo with an optical fibre-based
spectrofluorometer. Neither local nor systemic side-effects were observed for the applied conditions. All conditions used yielded a preferential
PpIX accumulation in the neoplastic tissue. Our clinical investigations indicate that with h-ALA a twofold increase of PpIX fluorescence
intensity can be observed using 20-fold lower concentrations as compared to ALA.
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in vivo and in vitro (Kloek et al, 1996; Peng et al, 1996; Gaullier et
al, 1997; Marti et al, 1998). These groups demonstrated that the
application of esterified ALA derivatives results in an up to 25-
fold increase in PpIX fluorescence levels as compared to ALA.
This report covers initial clinical investigations with 5-amino-
laevulinic acid hexylester hydrochloride (h-ALA)-induced
fluorescence PD in the human bladder. Following our preclinical
studies (Marti et al, 1999), we selected h-ALA from the multitude
of possible ALA-alkylesters because it represents a good compro-
mise between water–urine solubility and sufficient PpIX formation
capacity at low doses. Furthermore, h-ALA has been shown to lead
to a homogenous distribution of PpIX-related fluorescence over
the entire urothelium in our pig bladder model (Marti et al, 1998).
In addition, it can be synthesized simply from ALA and hexanol
(Kloek et al, 1997). The goal of this clinical pilot study was to test
h-ALA as a potential candidate for improving both the PD and
PDT in the urinary bladder. Therefore, topical application of h-
ALA should result in higher PpIX formation than is the case with
the same amount of ALA. It should enable shorter times between
instillation and examination and lower drug concentrations while
retaining the outstanding selectivity of ALA. This work presents a
preliminary optimization of h-ALA-induced PpIX in respect to the
resulting fluorescence intensities. Both the influence of the
concentration and instillation time of h-ALA solutions on the total
amount of PpIX were determined in vivo by the use of an optical
fibre-based spectrofluorometer.
MATERIALS AND METHODS
Patients
Twenty-five patients (seven women and 18 men, four cases of
ordinary ALA and 21 cases of h-ALA) have been involved in this
first study conducted since August 1997. The mean age was 70
years, covering an age range of between 44 and 85. Local ethical
committee approval was granted for this study, and written consent
was obtained in each case.
Preparation and administration of ALA and h-ALA
ALA (99%) was purchased from Merck (Darmstadt, Germany).
Other chemicals (thionyl chloride 99% and 1-hexanol 99.9%) used
for the synthesis of h-ALA were ordered from Fluka Chemie AG
(Buchs, Switzerland) and were used without further purification.
The synthesis described here is a slight modification of the
methods reported recently (Takeya, 1992; Kloek et al, 1996). In
brief, 3.5 ml of thionyl chloride were added drop by drop under
stirring to an excess (~ 10 ml) of 1-hexanol cooled on ice in an
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Table 1 Experimental instillation conditions used in the first clinical trials with h-ALA and normalized
fluorescence levels on papillary tumours (pTa G2) obtained by normalization to reference cuvette
Patient Concentration Instillation Resting time Fluorescence
no. (mM) time (h) (h) signal (r.u.)
1 4 2 – 16.2
2 4 2 – 11.2
3 4 4 – 34.5
4 4 4 – 20.5
5b 8 2 – 22.1
38.4
6 8 2 – 36.2
7 8 2 – 46.7
88 2 – –
9b 8 2 2 151.1
102.0
10 8 2 2 115.8
11 8 2 2 147.5
12 8 4 – 66.4
13 8 4 – 72.6
14 8 4 – 63.4
15 8 4 – 73.8
16 8 4 – 94.4
17 8 4 – 77.1
18 8 4 2 102.7
19 8 4 2 95.0
20 16 2 – 15.8
21 16 2 – 16.7
22 180a 4 2 54.0
23 180a 4 2 43.6
24 180a 4 2 46.2
25 180a 4 2 45.3
aInstillation of the 180 mM solution of ALA.bPatient with two papillary tumours.argon atmosphere. The solution was stirred for a further 30min to
bring the reaction to completion; after warming up to room
temperature, 2.5g of ALA (Mr = 167.6g mol–1) were added to the
solution. The suspension was then stirred overnight at room
temperature under argon. The final phase of the reaction was
controlled on-line by thin layer chromatography (TLC) (TLC foils;
Schleicher & Schuell, Merck, Darmstadt, Germany) in
CH2Cl2/MeOH (9:1) stained by KMnO4 (Rf = 0.6). Once the reac-
tion was complete, the solvent and hexylchloride were removed
under reduced pressure (~ 0.5 torr). The viscous residue was
dissolved in warm methanol. Then a small amount of methanol
was evaporated until the first crystals of the reaction product
appeared. A small quantity of diethylether was added and h-ALA
was allowed to crystallize on ice. This dissolving and recrystal-
lizing procedure was then subsequently repeated until only one
spot was recognized on the TLC, yielding 80–90% of h-ALA
(Mr = 251.8gmol–1) as a white powder. The product was charac-
terized by proton nuclear magnetic resonance (1H-NMR) with a
400MHz (Bruker, Germany) spectrometer and identified as
5-aminolaevulinic acid hexylester hydrochloride. The purity
(> 95%) was further verified by high performance liquid chro-
matography (HPLC) with UV/VIS detection at 270 and 350nm
respectively (data not shown). No other products were observed.
The ALA solutions were administered in accordance with
standard protocol used in Lausanne’s CHUV Hospital (Jichlinski
et al, 1997). In brief, 1500mg of ALA were dissolved in 38ml of
sterile water. Five millilitres of phosphate-buffered saline (PBS)
were added and the pH was adjusted with a further 7ml of aqueous
sodium hydroxide (1N) to a value of pH 5.3. This solution with a
concentration of 180mMof ALA was sterilized by filtration
through a Millipore filter (Millipore, Millex GS 0.22m) and stored
at –18°C 1 day before measurements were conducted. The solution
was instilled into patients’ bladders using a 16 French Foley
catheter 6h prior to photodetection. Patients were asked to retain
the solution for 4h. Their bladders were evacuated 2h prior to
treatment.
Depending on the prodrug concentration to be applied, 50–
200mg (i.e. 4–16mM) of crystalline h-ALA were dissolved in
35ml of water. Then 13ml of PBS were added to the aqueous
solution and adjusted with 0.1 N hydrochloric acid to give the
same pH value of 5.3. The solutions were instilled as described
above. Table 1 summarizes the different conditions under which
ALA and h-ALA were applied. All patients treated with ALA (four
cases) and some instilled with h-ALA (five cases) had a supplemen-
tary resting time of 2h after being exposed to the drug solution.
Procedure
Bladder inspection under white light illumination
Prior to further treatment or measurement, the actual status of the
bladder was documented under white light illumination. The frame
accumulation colour CCD camera (Storz, Tuttlingen, Germany),
connected to a video recorder (JVC, Japan) and an RGB monitor
(Sony, Japan) was plugged directly into the ocular of a 23.5 French
cystoscope (Storz PDD, Tuttlingen, Germany) to record the stan-
dard endoscopic colour image.
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Figure 1Schematic view of the optical fibre-based spectrofluorometerFluorescence spectroscopy
Fluorescence emission spectra were recorded with an optical fibre-
based spectrofluorometer based on a Peltier-cooled CCD coupled
to a spectrograph (Cromex 250, SI Instruments, Germany). The
experimental setup is shown in Figure 1. Arranged on a trolley, the
whole setup can be easily transported. Excitation light (lex =
405 nm) from a 75 W high-pressure Xenon lamp (UXL-75 XE,
Ushio Inc., Japan) was spectrally resolved by a quarter meter
monochromator (Chromex 250, SI Instruments, Germany) with a
bandwidth of 5 nm and an excitation filter, SCHOTT BG3 (Schott
AG, Mainz, Germany), mounted on a filter wheel. A stepper motor
(SMC 100, Princeton Instruments Inc., USA) controlled this
excitation filter wheel, which was equipped with different low-
pass filters installed to purify the excitation light. Fully reflective
mirrors and a dichroic mirror (Reynard DC 450; Reynard, USA),
mounted on a second filter wheel, were used to feed the light into
a 600 mm core silicone-clad silica fibre with perpendicular
polished end-faces. Excitation energy measured at the distal end
of the fibre tip was determined with a calibrated power-meter
(Optical Power Meter 840, Newport, USA). Fluorescence emitted
by any sample was collected with the same fibre and separated
from the excitation light by the dichroic optics described above. A
long-pass filter (Reynard FG 455) mounted on a third filter wheel
made further spectral separation, virtually eliminating all reflected
excitation light prior to acquisition. This filter setup allows the
acquisition of fluorescence emission spectra between 450 and
900 nm. Detection based on this combination enables fast data
acquisition combined with a low level of noise. The whole setup
and data acquisition was controlled by a 486 personal computer
using CSMA software (SI Instruments GmbH, Germany).
An aqueous solution of Rhodamine B (c = 1 ´ 10–6 mol l–1) in a
10 mm quartz cuvette was used as a reference. Emission spectra of
the reference were recorded before and after each measurement.
All measurements were normalized to the peak value of the
reference to give comparable results corrected for day-to-day
fluctuations of the excitation light energy or detection pathway
alignment.
After inspection of the bladder under white light, the distal end
of the fibre was introduced via the biopsy channel of the cysto-
scope. A background measurement was performed in the centre of
the bladder to allow the correction of the spectra for parasitic light
and fluorescence generated by the fibre itself. Then the physician
brought the distal end of the fibre directly into contact with the
bladder wall.
Bladder inspection under violet light illumination
After measurement of the fluorescence spectra (see below) of
healthy, cancerous and suspicious areas in the bladder, the camera
was equipped with a long-pass filter (1 > 520 nm; Wratten filter
No. 12, Kodak, Rochester, USA), positioned between the ocular of
the cystoscope and the CCD-Chip. A footswitch allows the physi-
cian to place a bandpass filter (380–450 nm) in front of the 300 W
Xenon arc lamp (Storz, Tuttlingen, Germany) to give about
150 mW of violet light at the end of the cystoscope. Excitation
with violet light generated a visible pale-green autofluorescence of
the healthy mucosa. As a result of the absorption of autofluores-
cence, the blood vessels of the lamina propria appear somewhat
darker. Filtration of the light below 520 nm allows these sites to be
distinguishable from zones containing high PpIX concentrations,
appearing in a clear, bright, fluorescing red. To improve the
fluorescence images, the camera was switched into frame
accumulation mode for enhanced sensitivity. The integration times
ranged from one-eighth to one-half of a second, depending on
observation distance.
Biopsy sampling and pathology
Prior to transurethral resection of the bladder wall (TURB), a total
number of 109 biopsies from fluorescent and non-fluorescent
areas (average 5.2 per patient; guided by light-induced fluores-
cence after excitation at 405 nm) were taken from the patients
treated with h-ALA solutions. Macroscopic fluorescence findings
and locations were documented for each biopsy. All samples were
sent for histopathological examination. The urothelial carcinomas
were graded and staged according to the World Health
Organization (WHO) 1973 classification (Mostofio et al, 1973)
and the UICC/AJC 1992 system (Hermanek and Subin 1992)
respectively. Flat intra-epithelial neoplastic lesions were graded
according to the criteria of Nagy et al (1982) and classified as
grade 1 (mild dysplasia), grade 2 (moderate dyslasia), grade 3
(marked dysplasia) and carcinoma in situ.
RESULTS
Macroscopic findings
All aqueous solutions of h-ALA stayed clear and colourless until
use. Neither systemic nor local reactions following the examina-
tion with both h-ALA and ALA were observed under the condi-
tions used in this study. Even the highest drug dose administered
(16 mM) of h-ALA was well tolerated. h-ALA-induced synthesis
of PpIX was observed in each patient. All papillary and planar
tumours, also visible under white light cystoscopy, showed bright
red fluorescence. This red fluorescence was found to demarcate
the outline of the urothelial lesions with high precision. Using the
violet light of the filtered Xenon arc lamp, it was possible to
perform both fluorescence-guided biopsies as well as accurate
resections of targeted tissues. Qualitatively, all conditions tested
resulted in a clearly visible contrast between healthy and diseased
sites of the bladder wall.
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Table 2 Correlation between histopathological finding and fluorescence
diagnosis following h-ALA instillation
Histopathological Total number Fluorescence Fluorescence
findings of biopsies positive negative
Healthy mucosa 28 5 23
Metaplasia 1 1 –
Hyperplasia 3 3 –
Dysplasia G1 12 10 2
Dysplasia G2 5 3 2
Dysplasia G3 2 2 –
CIS 11 9 2
pTa G1 8 8 –
pTa G2 14 14 –
pTa G3 19 19 –
pT1 G2–G3 4 4 –
pT2a 2 2 –
Total 109 80 29Figure 2 demonstrates the advantageous use of h-ALA- induced
PpIX for the fluorescence diagnosis of human bladder cancer. The
two pictures show a sequence of a white light (Figure 2A) and a
violet light (Figure 2B) examination after instillation of 8 mM of
h-ALA over a period of 2 h (patient no. 10). White light illumina-
tion shows two papillary tumours (pTa G2) situated below the air
bubble of the bladder under investigation. Fluorescence PD of the
same area (Figure 2B) indicates a further lesion [flat papillary
tumour (pTa G2)] which is barely detectable under white light.
Fluorescence findings and histopathological diagnosis
A total of 109 biopsies were taken under light-induced fluores-
cence from patients after instillation with h-ALA solutions. The
correlation between the fluorescence findings and the histopatho-
logical analysis is summarized in Table 2. Thirty-two tissue
samples were excised from healthy areas of the bladders investi-
gated, containing eight samples, which were considered to be
fluorescent. Histopathological diagnosis of the latter samples indi-
cates the reasons for these ‘false positive’ responses. All these
specimens showed tissular structures known for a higher cellular
turnover, e.g. metaplasias, hyperplasias, chronic inflammation, or
scar formation. In total, only six of the 77 biopsies taken from
malignant and premalignant sites were not fluorescing. Three of
these ‘false negative’ responses can be explained by nonoptimized
conditions with regard to the concentrations of h-ALA applied
(two moderate dysplasias; patient no. 4) as well as non-optimal
incubation times (CIS; patient no. 1). A further CIS was missed
(patient no. 13) probably due to an unusually long period of white
light illumination preceding photodetection, resulting in the
photobleaching of PpIX. Without exception, histopathologically-
staged pta G1 or higher samples were found by fluorescence
photodetection.
Fluorescence spectroscopy
Fluorescence emission spectra were measured on a total number of
24 patients (20 h-ALA, four ALA) (Table 1). ALA- and h-ALA-
induced porphyrins were excited at 405 nm on both healthy and
malignant areas in the human bladder. The emission from the
urothelial surface was spectrally resolved between 450 and
800 nm. A comparison of the emission spectra after ALA and
h-ALA exposure is plotted in Figure 3. The total fluorescence
intensity is normalized to the reference. As shown in this Figure,
the characteristic emission bands of PpIX at l = 635 nm and
l = 708 nm after excitation in the Soret Band are clearly visible.
According to the spectral shape, the fluorescence is attributed to
PpIX. In none of the spectra recorded in vivo, an indication of
porphyrins other than PpIX could be found. Depending on the
duration of white and violet light examinations before fluorescence
ALA hexylester based photodetection of human bladder cancer 189
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Figure 3 (A) Fluorescence spectra of h-ALA-induced PpIX (lex = 405 nm)
in normal mucosa (– – – –) and a papillary tumour (pTa G2, ——) after 4 h of
instillation with 8 mM h-ALA (. . . .): a fluorescence peak (*) at 670 nm
becomes visible due to photobleaching of PpIX. (B) Fluorescence spectra of
ALA-induced PpIX (lex = 405 nm) in a papillary tumour (pTa G2, ——) after
6 h of installation with 180 mM ALA)
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Figure 2 Endoscopic view of a flat papillary tumour (pTa G2) after 2 h of
h-ALA exposure (for description see text) under (A) white light, (B) violet
light examinationmeasurements, a peak, attributed to a PpIX photobleaching
product, of around 665–675 nm appeared (dotted line in Figure
3A). The appearance of this supplementary fluorescence peak
results in a line broadening because of overlapping fluorescence
emission peaks and may suggest some degree of heterogeneity.
In addition to the fluorescence emission spectra recorded on a
papillary tumour pTa G2 after 4 h of h-ALA exposure, the corre-
sponding spectra obtained on a healthy area were plotted (dashed
line in Figure 3A). From these spectra, it can be seen that the
healthy mucosa’s autofluorescence of around 513 nm exceeds the
two typical fluorescence peaks of PpIX at 636 nm and 708 nm. All
samples taken from sites with these fluorescence characteristics
were confirmed as healthy after histopathological examination.
Evaluation of all fluorescence data available reveals that papillary
tumour had the highest emission intensities. Premalignant lesions,
such as dysplasias and carcinoma in situ, generally showed lower
PpIX fluorescence intensities compared to malignant lesions.
However, no direct relationship has been discovered between
histopathological grading and relative fluorescence values.
Effect of exposure time and concentration
Three different solutions containing 50 mg (4 mM, four patients),
100 mg (8 mM, 15 patients) and 200 mg (16 mM, two patients) of
h-ALA in 50 ml of the solvent were instilled in human bladders
between 2 and 6 h prior to the fluorescence measurements
(Table 1). Increased red fluorescence due to enhanced PpIX
formation in pre-malignant and malignant lesions compared to the
surrounding healthy sites was observed at all applied conditions.
In order to quantify the resulting PpIX fluorescence, emission
spectra were collected from different sites of the treated bladders.
The fluorescence intensities of papillary tumours pTa graded G2
or G3 at 636 nm were chosen as standard in order to determine
the influence of the different treatment conditions applied. This
selection is based on the presence of this type of lesion in each
bladder examined. Table 1 summarizes the influence of the
different conditions on the relative fluorescence intensities of
the PpIX emission band at 636 nm.
Analysis of the data available from patients exposed for
2 h (patient nos 1, 2, 5, 6, 7, 20 and 21) to different h-ALA concen-
trations indicates a strong concentration dependent on the PpIX
fluorescence. It appears that, within 2 h, a solution of 8 mM h-ALA
generates the highest fluorescence levels as compared to 4 mM and
16 mM of h-ALA. In Figure 4, the time course of the relative
fluorescence intensity is plotted for h-ALA concentrations of
4m M and 8 mM. An increase of fluorescence intensity with instil-
lation time was observed in the two solutions. In addition, Figure 4
shows that, taking both the total fluorescence and the slope of the
graphs into consideration, an instillation of 8 mM h-ALA solution
is more efficient than that of a 4 mM solution.
In the course of our preliminary clinical study, a total of four
patients (nos 8–11) were instilled under slightly different condi-
tions. The patients’ bladders were exposed to the solutions for 2 h.
Following this exposure time, the bladders were emptied and the
patients were allowed a supplementary resting time of 2 h. From
Figure 4, it is clear that following this ‘(2+2)-concept’ signifi-
cantly enhanced fluorescence levels can be obtained compared to
permanent exposure to the drug for 4 h.
The comparison of the relative fluorescence intensities of an
8m M h-ALA solution and a 180 mM solution of ALA under
similar conditions (4 h of instillation, 2 h of supplementary resting
time) clearly demonstrates the advantage of using h-ALA. A
treatment under these conditions with a topical 8 mM h-ALA
solution resulted in a twofold increase of the fluorescence signal as
compared to topical 180 mM ALA. After only 4 h of h-ALA
exposure (8 mM), the relative fluorescence intensity already
exceeded that induced by ALA (180 mM) 6 h after instillation.
DISCUSSION
Bladder cancer is a fairly common disease, appearing between the
ages of 50 and 70 (Richie et al, 1989; Levi, 1993). This cancer,
characterized by a high incidence (Levi, 1993), can appear in
many distinct morphological forms, single or multiple, visible
such as papillary or invisible such as ‘flat’ atypical lesions, mainly
represented by low- or high-grade dysplasia or CIS. Bladder
tumour multiplicity and the presence of these different forms of
atypia are indicators of poor disease prognosis. Recognition of all
visible or invisible lesions is therefore a prerequisite for any kind
of treatment, with the aim of reducing the risk of progression or
the rate of recurrence.
Although topical application of ALA has proved to be a helpful
and reliable tool in fluorescence photodetection of invisible
lesions in human bladder disease (Kriegmair et al, 1994; Jichlinski
et al, 1996), some problems remain due to ALA’s poor bioavail-
ability. A small hydrophilic amino acid like ALA does not pene-
trate into all tissue compartments with great ease. Hence its
concentration in tissue may remain relatively low and its distribu-
tion somewhat heterogeneous. Consequently, high drug doses over
long instillation periods have to be used.
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Figure 4 Effect of instillation time on the relative PpIX fluorescence
intensity at 636 nm in papillary tumours (pTa G2) (n n: 8 mM h-ALA; l l:
4m M h-ALA; s s: 8 mM h-ALA (2 h of instillation + 2 h of resting time); t t:
180 mM ALA)Three different concepts have been proposed to enhance the
ALA-induced PpIX formation in deeper layers of the target tissue.
Two of them are based on the use of chemicals, given along with
ALA, in order to enhance both its penetration into deeper tissue
layers and/or the total PpIX accumulation. This transepithelial
penetration enhancement can be achieved either by prior dimethyl
sulphoxide exposure of the targeted area (Peng et al, 1995) or by
encapsulation of ALA into liposomes (Fukuda et al, 1992). The
second approach uses agents interfering directly with the biosyn-
thetic pathway of haem. Tetrapyrrol modulators, such as 1,10-
phenanthroline (Rebeiz et al, 1996) and allyl-isopropyl-acetamide
(AIA) (Schoenfeld et al, 1994) stimulating the enzymatic activity
associated with PpIX formation. Iron chelators (e.g. ethylene-
diaminotetraacetic acid (EDTA) (Hanania and Malik, 1992;
Orenstein et al, 1995; Warloe et al, 1995), desferrioxamine (DFO)
(Ortel et al, 1993) CP94 (Chang et al, 1997) have been shown to
increase PpIX concentration by preventing the ferrochelatase-
mediated insertion of iron into the tetrapyrrol ring. This study
followed a third approach, based on the thesis that the transforma-
tion of the hydrophilic ALA into more lipophilic prodrugs will
enhance drug uptake.
In view of the results obtained using esters of ALA in vitro
(Kloek et al, 1996; Gaullier et al, 1997; Marti et al, 1999; Tyrrell et
al, 1993) and in vivo (Kloek et al, 1996; Peng et al, 1996), it
appeared reasonable to envisage developing such a substance for
clinical tests in which superficial bladder carcinoma is detected by
fluorescence and possibly even treated by PDT. From the variety
of derivatives recently tested in our laboratory (Marti et al, 1999),
we selected h-ALA as it represents a good compromise between
water–urine solubility and lipophilicity. It also gave an excellent
in-vitro dose drug response compared to ALA solutions.
Furthermore, it can be synthesized with a fairly high yield and low
cost. The goal of this first clinical study with h-ALA in urology
was to evaluate the feasibility of fluorescence photodetection with
this new agent and the advantages achieved by instillation of
h-ALA as compared to ALA for use in the human bladder.
One criterion for the use of h-ALA as a potential candidate in
replacing ALA, is the preservation of the outstanding selectivity of
ALA-induced PpIX for malignant and pre-malignant tissues.
Confirmed by histopathological examination, we have demon-
strated that the fluorescence of PpIX in the urothelium induced by
intravesically administered h-ALA correlated significantly with
neoplastic lesions and was suitable for the detection of papillary
tumours as well as for dysplasia and carcinoma in situ. The 7%
rate of false negative responses found in the present study is
comparable to the value given by Jichlinski et al in 1997 and
slightly higher than that presented by the Munich group
(Kriegmair et al, 1996). A total number of 28 biopsies were taken
from areas proven to be benign. Only five of these samples
revealed an enhanced red fluorescence under violet light irradia-
tion, yielding a rate of falsely positive fluorescence findings of
17%. This result seems to be quite small compared to both the
results of Kriegmair et al (1996) and Jichlinski et al (1997). But it
may be explained by the small number of biopsies taken, or the
fact that the fluorescence induced by the long-chain esters was
found to be limited to the site of application (Peng et al, 1996),
hence no supplementary PpIX build-up from systemic ALA
uptake is observed.
Clinical fluorescence spectroscopy has been used for measuring
the PpIX accumulation kinetics, indicating an increase of h-ALA-
induced PpIX with time in the human bladder within 6 h. A
quantitative comparison of the fluorescence intensities at 636 nm
following similar instillation conditions with solutions of 180 mM
of ALA or 8 mM of h-ALA, respectively, clearly shows the advan-
tages of h-ALA-induced PpIX. The more than twofold increase of
the fluorescence signal due to the use of h-ALA is in good
agreement with the in vivo results of Kloek et al (1996).
The time course of the PpIX fluorescence intensity in neoplastic
tissues shows that, following 8 mM h-ALA exposure for 2 or 4 h,
synthesis of PpIX continues within almost 2 h after termination of
the instillation. In this time range, the fluorescence intensity
increases 400% (2 h of exposure, 2 h of resting time) and 25%
(4 h of exposure, 2 h of resting time) respectively.
The significant increase of the fluorescence signal using the
‘(2+2)-concept’ as compared to a permanent exposure to drug for
4 h, as well as the strong dependence on the instilled h-ALA
concentration, can be explained by an interference of high ALA
concentrations with the biosynthetic pathway of haem. This obser-
vation was confirmed by in vitro experiments made by Gaullier
et al (1997) and Marti et al (1999) with several ALA esters
including h-ALA. Whereas the transport of ALA across the lipid
bilayer of cell membranes probably represents a bottleneck in the
PpIX formation, the enhanced uptake of lipophilic h-ALA may
saturate the intracellular PpIX biosynthesis. This saturation might
cause a negative feedback to enzymatic activity. Furthermore, high
intracellular ALA concentrations have been shown to be cytotoxic.
A high cellular ALA content may induce the release of Ca2+ from
mitochondria, mitochondria swelling and uncouple respiration
(Hermes-Lima, 1995). It can also cause ferritin iron release (Berg
et al, 1996) or mediate the formation of 8-hydroxy-2¢-deoxyguano-
sine in DNA (Fraga et al, 1994).
The results presented in this study have shown that a 2 h instil-
lation of h-ALA (8 mM) provides sufficient PpIX fluorescence for
reliable photodetection of malignant and pre-malignant lesions.
This reduction in instillation time to only 2 h significantly
increases the patient’s comfort. Moreover, this makes outpatient
treatment feasible and helps to cut costs in view of the excessively
increasing cost of hospitalization. Finally, the reduction of the drug
dose will decrease drug cost and the potential risk of mild compli-
cations provoked by ALA, recently reported by Rick et al (1997).
While for reliable fluorescence photodetection a 2 h instillation
of 8 mM h-ALA has been shown to give satisfactory results, other
conditions must be fulfilled with respect to an efficient bladder
cancer therapy by PDT. Among other factors, the two key parame-
ters of high concentration of the photosensitizer and its homoge-
neous distribution in the target tissue play a major role for the
effectiveness of PDT.
Fluorescence microscopic studies showed that, after topical
application of ALA, the PpIX was restricted to the superficial
layers of the bladder tumours (Steinbach et al, 1994). On the
contrary, preliminary fluorescence microscopic studies on some
biopsies, taken in this study (data not shown), as well as the in
vitro studies of Marti et al (1999) demonstrated homogeneously
distributed PpIX fluorescence over the entire urothelium after
topical application of h-ALA solutions.
Considering the photobleaching of porphyrins during irradiation
(Rotomski et al, 1996; Bezdetnaya et al, 1996; Moan et al, 1997), a
threshold concentration of PpIX necessary for tissue destruction,
and the high selectivity of h-ALA-induced PpIX, a small PpIX
amount in healthy areas of the bladder, observed in this study will
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twofold increase of PpIX fluorescence after 6 h in neoplastic
tissues by using h-ALA may further enhance the PDT effect as
compared to the use of ALA. The latter appeared insufficient as
observed in recent studies (Kriegmair et al, 1996).
It can be concluded that the use of h-ALA is a promising way to
improve the photodetection of neoplastic and pre-neoplastic
lesions as compared to ALA. In future, h-ALA may replace the
use of ALA for clinical intravesical instillation because it is easy
to use, real time observation without major auxiliary devices is
possible and it is relatively cheap. Finally, it looks more promising
as a PDT agent than ALA itself.
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